ACC pipeline
What is next, and who is running it?
The next dated milestone on each program. A hollow marker is a registry primary completion date, not a company readout.
A black mark is a readout. A yellow mark is another company date. A circle is an approval or an FDA action date the source names. A hollow mark is a registry primary completion date.
ClassNone selected
21 of 23 programs on this timeline
202520262027202820292030Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Today
B7-H4-directed ADC 2
EMBLEM-1 first patients dosed, Oct 19, 2026
No dated milestone in 2025 to 2030
CXCR1/2 inhibitor 1
SX-682 + DocetaxelPhase 1/2
No dated milestone in 2025 to 2030
EGFR x MET bispecific antibody 1
AmivantamabPhase 2
No dated milestone in 2025 to 2030
gamma secretase inhibitor 1
No dated milestone in 2025 to 2030
HDAC inhibitor 1
HG146Phase 2
No dated milestone in 2025 to 2030
MDM2 inhibitor 1
APG-115 (alrizomadlin)Phase 1/2
No dated milestone in 2025 to 2030
multi-kinase TKI 1
Regorafenib (off Label)Phase 2
No dated milestone in 2025 to 2030
multi-kinase TKI with chemotherapy 1
No dated milestone in 2025 to 2030
MYB mRNA degrader 1
REM-422Phase 1/2
No dated milestone in 2025 to 2030
Nectin-4-directed ADC 1
Enfortumab VedotinPhase 2
No dated milestone in 2025 to 2030
pan-NOTCH transcription inhibitor 1
CB-103Phase 1/2
No dated milestone in 2025 to 2030
PD-1 x VEGF bispecific 1
IvonescimabPhase 2
No dated milestone in 2025 to 2030
PSMA radioligand 1
No dated milestone in 2025 to 2030
TrkA inhibitor 1
VMD-928Phase 1/2
No dated milestone in 2025 to 2030
TROP2-directed ADC 1
No dated milestone in 2025 to 2030
VEGFR multi-kinase TKI 1
Lenvatinib (off Label)Phase 2
No dated milestone in 2025 to 2030
VEGFR TKI 1
Axitinib (off Label)Phase 2
No dated milestone in 2025 to 2030
VEGFR/MET/TAM TKI 1
ZanzalintinibPhase 2
No dated milestone in 2025 to 2030
VEGFR2 TKI 2
RivoceranibTrials stopped
No dated milestone in 2025 to 2030
ApatinibPhase 2
No dated milestone in 2025 to 2030